Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (221-230 of 290) with videos related to

Pageof 29
Sort By:
Cancer Science|October 13, 2021
Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicineYutaka Shimazu, Shohei Mizuno, Shin-Ichi Fuchida, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Case Reports in Oncological Medicine|February 26, 2026
Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by ApalutamideYoshihisa Mimura, Takaomi Sanda, Rei Unno, et al.
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Cancer Science|November 27, 2025
Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple MyelomaToru Ebina, Masaki Ri, Yoshiaki Marumo, et al.
Experimental Hematology & Oncology|April 21, 2016
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialTatsuo Ichinohe, Yoshiaki Kuroda, Shinichiro Okamoto, et al.
European Journal of Haematology|November 6, 2013
Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse modelFumiko Mori, Takashi Ishida, Asahi Ito, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 24, 2021
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myelomaMitsuhito Hirano, Yoichi Imai, Yuta Kaito, et al.
Hematological Oncology|November 26, 2022
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs studyKazutaka Sunami, Shin-Ichi Fuchida, Kenshi Suzuki, et al.
Ejhaem|July 18, 2022
Clinical features of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single-center, retrospective observational studyTakafumi Nakayama, Yoshiko Oshima, Shigeru Kusumoto, et al.
Pageof 29

Showing results (221-230 of 290) with videos related to

Sort By:
Pageof 29
Cancer Science|October 13, 2021
Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicineYutaka Shimazu, Shohei Mizuno, Shin-Ichi Fuchida, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Case Reports in Oncological Medicine|February 26, 2026
Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by ApalutamideYoshihisa Mimura, Takaomi Sanda, Rei Unno, et al.
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Cancer Science|November 27, 2025
Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple MyelomaToru Ebina, Masaki Ri, Yoshiaki Marumo, et al.
Experimental Hematology & Oncology|April 21, 2016
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialTatsuo Ichinohe, Yoshiaki Kuroda, Shinichiro Okamoto, et al.
European Journal of Haematology|November 6, 2013
Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse modelFumiko Mori, Takashi Ishida, Asahi Ito, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 24, 2021
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myelomaMitsuhito Hirano, Yoichi Imai, Yuta Kaito, et al.
Hematological Oncology|November 26, 2022
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs studyKazutaka Sunami, Shin-Ichi Fuchida, Kenshi Suzuki, et al.
Ejhaem|July 18, 2022
Clinical features of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single-center, retrospective observational studyTakafumi Nakayama, Yoshiko Oshima, Shigeru Kusumoto, et al.
Pageof 29